Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > This Whole Board is Full Of Nutty Conspiracy Theories...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by bligickaon Jun 17, 2020 9:06pm
68 Views
Post# 31162928

RE:RE:RE:RE:RE:RE:RE:RE:RE:This Whole Board is Full Of Nutty Conspiracy Theories...

RE:RE:RE:RE:RE:RE:RE:RE:RE:This Whole Board is Full Of Nutty Conspiracy Theories...Great post, fight the good fight !!!
Valuehunter72 wrote:

So well put together 359.  


For those asking us to contact the company.....Pretty sure the company has made it very clear over the past few months that any contact with them will be promptly and politely replied to by answering the standard....Thanks for your interest, appreciate your support, can not disclose anything, stay safe.

Even when you tell them you own over a million shares.....they don't care.

After a while you give up reaching out to the company.  A company that seems to have gone silent and turned its back on the very shareholders that filled their coffers with 1.4 million in warrant money to advance the preclinical research that no further funding was required.

Apparantly some people get ticked off when other investors point that out after the company decides to dilute 100 million shares with another 80 million at a 10.5 cent average.

How dare any existing shareholders show displeasure to these actions?  You will take it and like it and shut up?????

Not the way I was raised.....sorry bro.  Learn to take other peoples opinions.  Take your thought police garbage elsewhere.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities